Amyloidosis Market Report and Forecast 2025-2034
Description
The amyloidosis market was valued at USD 4.35 Billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 8.09 Billion by 2034.
Amyloidosis Market Overview
Amyloidosis is a rare condition caused by the abnormal buildup of amyloid proteins in tissues and organs, leading to dysfunction and failure. Key growth drivers include rising prevalence among aging populations and advancements in specialized therapies. Major market trends involve expedited drug development along with the adoption of personalized medicine, and combination treatments. Moreover, rising R&D investments and regulatory incentives are reshaping the therapeutic landscape significantly.
Amyloidosis Market Growth Drivers
Rising Prevalence of Amyloidosis Drives Market Growth
The rising prevalence of systemic and localized amyloidosis, particularly among older adults, is a key growth driver. AL amyloidosis, representing 78% of cases, occurs at a rate of 1 case per 100,000 in Western countries, with approximately 1,275–3,200 new cases occurring annually in the United States. The increasing prevalence underscores the demand for improved diagnostics and novel treatments.
Amyloidosis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Shift Towards Targeted Therapies
In December 2023, AstraZeneca and Ionis received US FDA approval for Wainua (eplontersen) to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Based on the NEURO-TTRansform Phase III trial, Wainua demonstrated reductions in serum transthyretin (TTR) levels, improved neuropathy impairment, and quality of life. As the first self-administered treatment via auto-injector, it addressed a significant unmet medical need. With regulatory reviews ongoing in Europe and other regions, Wainua is set to expand global market opportunities, driving growth in targeted therapies for rare diseases and offering innovative solutions for improved patient outcomes.
Rising Demand for Personalized Medicine to Fuel Amyloidosis Market Demand
Advances in genomics, proteomics, and biomarker identification are enabling tailored treatments based on individual genetic profiles and disease subtypes. Personalized therapies enhance efficacy, reduce side effects, and drive patient adoption, boosting market growth and fostering innovation in amyloidosis treatment.
Adoption of Combination Therapies Expected to Propel Amyloidosis Market Growth
Combination therapies, integrating chemotherapy with monoclonal antibodies, proteasome inhibitors, or immunomodulatory drugs, are improving treatment outcomes by reducing amyloid deposits and enhancing organ function. This strategy is gaining traction among healthcare providers, driving market growth.
Biomarker Advancements Likely to Revolutionize Amyloidosis Market
Innovations in biomarker technologies are transforming amyloidosis diagnosis and treatment by enabling early detection, disease monitoring, and precision therapies. Biomarker advancements (supported by AI and machine learning) improve clinical trial efficiency, reduce diagnostic delays, and accelerate market growth.
Amyloidosis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Segmentation Based on Route of Administration to Witness Substantial Market Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. Among these, the oral administration is expected to lead the market. Oral medications, such as transthyretin stabilizers (e.g., Tafamidis), offer ease of use, reducing the need for hospital visits, high patient compliance, and cost-effectiveness. It allows for convenient at-home treatment. In addition, oral therapies provide a less invasive and more scalable option for long-term management, ensuring better patient adherence and improved outcomes.
Amyloidosis Market Analysis by Region
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The research and development activities in the pharmaceutical and biotechnology sectors are also contributing to significant growth in the region.
Leading Players in the Amyloidosis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer Inc.
Established in 1849 and headquartered in New York, USA, Pfizer is one of the key pharmaceutical companies. It has developed Vyndamax (tafamidis), a breakthrough therapy for transthyretin amyloidosis (ATTR)-slowing down the progression of the disease and improving the survival rate in hereditary and wild-type ATTR patients.
Johnson & Johnson Services, Inc.
Founded in 1886 and headquartered in New Jersey, USA, Johnson & Johnson is a major healthcare player. Its subsidiary, Janssen Pharmaceuticals, developed Daratumumab (Darzalex), a monoclonal antibody that targets plasma cells, thereby reducing amyloid protein production and effectively treating light-chain (AL) amyloidosis.
Takeda Pharmaceutical Company Limited
Takeda, based in Tokyo, Japan, is an international biopharmaceutical leader, founded in 1781. Its products for AL amyloidosis treatment include Ninlaro (ixazomib). It aims to be less invasive by providing an oral option to improve patients' outcomes in combination.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, located in New York, USA, was established in 1887. It is focused on innovative therapies for people and engages in the development of immunomodulatory therapies and combination therapies for AL amyloidosis and utilizes its oncological and hematological experience to improve disease management and survival rates for patients.
Other companies include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi, Alnylam Pharmaceuticals, Inc., and Prothena.
Key Questions Answered in the Amyloidosis Market
Amyloidosis Market Overview
Amyloidosis is a rare condition caused by the abnormal buildup of amyloid proteins in tissues and organs, leading to dysfunction and failure. Key growth drivers include rising prevalence among aging populations and advancements in specialized therapies. Major market trends involve expedited drug development along with the adoption of personalized medicine, and combination treatments. Moreover, rising R&D investments and regulatory incentives are reshaping the therapeutic landscape significantly.
Amyloidosis Market Growth Drivers
Rising Prevalence of Amyloidosis Drives Market Growth
The rising prevalence of systemic and localized amyloidosis, particularly among older adults, is a key growth driver. AL amyloidosis, representing 78% of cases, occurs at a rate of 1 case per 100,000 in Western countries, with approximately 1,275–3,200 new cases occurring annually in the United States. The increasing prevalence underscores the demand for improved diagnostics and novel treatments.
Amyloidosis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Shift Towards Targeted Therapies
In December 2023, AstraZeneca and Ionis received US FDA approval for Wainua (eplontersen) to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Based on the NEURO-TTRansform Phase III trial, Wainua demonstrated reductions in serum transthyretin (TTR) levels, improved neuropathy impairment, and quality of life. As the first self-administered treatment via auto-injector, it addressed a significant unmet medical need. With regulatory reviews ongoing in Europe and other regions, Wainua is set to expand global market opportunities, driving growth in targeted therapies for rare diseases and offering innovative solutions for improved patient outcomes.
Rising Demand for Personalized Medicine to Fuel Amyloidosis Market Demand
Advances in genomics, proteomics, and biomarker identification are enabling tailored treatments based on individual genetic profiles and disease subtypes. Personalized therapies enhance efficacy, reduce side effects, and drive patient adoption, boosting market growth and fostering innovation in amyloidosis treatment.
Adoption of Combination Therapies Expected to Propel Amyloidosis Market Growth
Combination therapies, integrating chemotherapy with monoclonal antibodies, proteasome inhibitors, or immunomodulatory drugs, are improving treatment outcomes by reducing amyloid deposits and enhancing organ function. This strategy is gaining traction among healthcare providers, driving market growth.
Biomarker Advancements Likely to Revolutionize Amyloidosis Market
Innovations in biomarker technologies are transforming amyloidosis diagnosis and treatment by enabling early detection, disease monitoring, and precision therapies. Biomarker advancements (supported by AI and machine learning) improve clinical trial efficiency, reduce diagnostic delays, and accelerate market growth.
Amyloidosis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- AA Amyloidosis
- Others
- Targeted Therapy
- Chemotherapy
- Stem Cell Transplant
- Medication
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Others
- Others
- Oral
- Parenteral
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Segmentation Based on Route of Administration to Witness Substantial Market Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. Among these, the oral administration is expected to lead the market. Oral medications, such as transthyretin stabilizers (e.g., Tafamidis), offer ease of use, reducing the need for hospital visits, high patient compliance, and cost-effectiveness. It allows for convenient at-home treatment. In addition, oral therapies provide a less invasive and more scalable option for long-term management, ensuring better patient adherence and improved outcomes.
Amyloidosis Market Analysis by Region
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The research and development activities in the pharmaceutical and biotechnology sectors are also contributing to significant growth in the region.
Leading Players in the Amyloidosis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer Inc.
Established in 1849 and headquartered in New York, USA, Pfizer is one of the key pharmaceutical companies. It has developed Vyndamax (tafamidis), a breakthrough therapy for transthyretin amyloidosis (ATTR)-slowing down the progression of the disease and improving the survival rate in hereditary and wild-type ATTR patients.
Johnson & Johnson Services, Inc.
Founded in 1886 and headquartered in New Jersey, USA, Johnson & Johnson is a major healthcare player. Its subsidiary, Janssen Pharmaceuticals, developed Daratumumab (Darzalex), a monoclonal antibody that targets plasma cells, thereby reducing amyloid protein production and effectively treating light-chain (AL) amyloidosis.
Takeda Pharmaceutical Company Limited
Takeda, based in Tokyo, Japan, is an international biopharmaceutical leader, founded in 1781. Its products for AL amyloidosis treatment include Ninlaro (ixazomib). It aims to be less invasive by providing an oral option to improve patients' outcomes in combination.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, located in New York, USA, was established in 1887. It is focused on innovative therapies for people and engages in the development of immunomodulatory therapies and combination therapies for AL amyloidosis and utilizes its oncological and hematological experience to improve disease management and survival rates for patients.
Other companies include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi, Alnylam Pharmaceuticals, Inc., and Prothena.
Key Questions Answered in the Amyloidosis Market
- What was the amyloidosis market value in 2024?
- What is the amyloidosis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market breakup based on the treatment type?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the distribution channel?
- What is the market segmentation based on the end user?
- What are the major factors aiding the amyloidosis market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major amyloidosis market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the amyloidosis market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the key treatment trends for AL amyloidosis?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Amyloidosis Market Overview: 8 Major Market
- 3.1 Amyloidosis Market Historical Value (2018-2024)
- 3.2 Amyloidosis Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Amyloidosis Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Amyloidosis Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Mortality by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Amyloidosis Market Landscape: 8 Major Market*
- 8.1 Amyloidosis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Amyloidosis Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Amyloidosis Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Amyloidosis Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Amyloidosis Market Segmentation: 8 Major Markets
- 12.1 Amyloidosis Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 12.1.3 AA Amyloidosis
- 12.1.4 Others
- 12.2 Amyloidosis Market (2018-2034) by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Chemotherapy
- 12.2.3 Targeted Therapy
- 12.2.4 Stem Cell Transplant
- 12.2.5 Medication
- 12.2.5.1 Transthyretin Transport Inhibitor
- 12.2.5.2 Immunomodulatory Drugs
- 12.2.5.3 Monoclonal Antibodies
- 12.2.5.4 Proteasome Inhibitors
- 12.2.5.5 Others
- 12.2.6 Others
- 12.3 Amyloidosis Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.4 Amyloidosis Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacies
- 12.4.3 Retail Pharmacies
- 12.4.4 Others
- 12.5 Amyloidosis Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Hospitals
- 12.5.3 Specialty Clinics
- 12.5.4 Academic and Research Institutes
- 12.5.5 Others
- 12.6 Amyloidosis Market (2018-2034) by Country
- 12.6.1 Market Overview
- 12.6.2 United States
- 12.6.3 Germany
- 12.6.4 France
- 12.6.5 Italy
- 12.6.6 Spain
- 12.6.7 United Kingdom
- 12.6.8 Japan
- 12.6.9 India
- 13 United States Amyloidosis Market (218-2034)
- 13.1 United States Amyloidosis Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 13.1.3 AA Amyloidosis
- 13.1.4 Others
- 13.2 United States Amyloidosis Market (2018-2034) by Treatment Type
- 13.2.1 Market Overview
- 13.2.2 Chemotherapy
- 13.2.3 Targeted Therapy
- 13.2.4 Stem Cell Transplant
- 13.2.5 Medication
- 13.2.5.1 Transthyretin Transport Inhibitor
- 13.2.5.2 Immunomodulatory Drugs
- 13.2.5.3 Monoclonal Antibodies
- 13.2.5.4 Proteasome Inhibitors
- 13.2.5.5 Others
- 13.2.6 Others
- 13.3 United States Amyloidosis Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Parenteral
- 13.4 United States Amyloidosis Market (2018-2034) by Distribution Channel
- 13.4.1 Market Overview
- 13.4.2 Hospital Pharmacies
- 13.4.3 Retail Pharmacies
- 13.4.4 Others
- 13.5 United States Amyloidosis Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Academic and Research Institutes
- 13.5.5 Others
- 14 United Kingdom Amyloidosis Market (218-2034)
- 14.1 United Kingdom Amyloidosis Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 14.1.3 AA Amyloidosis
- 14.1.4 Others
- 14.2 United Kingdom Amyloidosis Market (2018-2034) by Treatment Type
- 14.2.1 Market Overview
- 14.2.2 Chemotherapy
- 14.2.3 Targeted Therapy
- 14.2.4 Stem Cell Transplant
- 14.2.5 Medication
- 14.2.5.1 Transthyretin Transport Inhibitor
- 14.2.5.2 Immunomodulatory Drugs
- 14.2.5.3 Monoclonal Antibodies
- 14.2.5.4 Proteasome Inhibitors
- 14.2.5.5 Others
- 14.2.6 Others
- 14.3 United Kingdom Amyloidosis Market (2018-2034) by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.3 Parenteral
- 14.4 United Kingdom Amyloidosis Market (2018-2034) by Distribution Channel
- 14.4.1 Market Overview
- 14.4.2 Hospital Pharmacies
- 14.4.3 Retail Pharmacies
- 14.4.4 Others
- 14.5 United Kingdom Amyloidosis Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Specialty Clinics
- 14.5.4 Academic and Research Institutes
- 14.5.5 Others
- 15 Germany Amyloidosis Market (218-2034)
- 15.1 Germany Amyloidosis Market (2018-2034) by Type
- 15.1.1 Market Overview
- 15.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 15.1.3 AA Amyloidosis
- 15.1.4 Others
- 15.2 Germany Amyloidosis Market (2018-2034) by Treatment Type
- 15.2.1 Market Overview
- 15.2.2 Chemotherapy
- 15.2.3 Targeted Therapy
- 15.2.4 Stem Cell Transplant
- 15.2.5 Medication
- 15.2.5.1 Transthyretin Transport Inhibitor
- 15.2.5.2 Immunomodulatory Drugs
- 15.2.5.3 Monoclonal Antibodies
- 15.2.5.4 Proteasome Inhibitors
- 15.2.5.5 Others
- 15.2.6 Others
- 15.3 Germany Amyloidosis Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Parenteral
- 15.4 Germany Amyloidosis Market (2018-2034) by Distribution Channel
- 15.4.1 Market Overview
- 15.4.2 Hospital Pharmacies
- 15.4.3 Retail Pharmacies
- 15.4.4 Others
- 15.5 Germany Amyloidosis Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Specialty Clinics
- 15.5.4 Academic and Research Institutes
- 15.5.5 Others
- 16 France Amyloidosis Market (218-2034)
- 16.1 France Amyloidosis Market (2018-2034) by Type
- 16.1.1 Market Overview
- 16.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 16.1.3 AA Amyloidosis
- 16.1.4 Others
- 16.2 France Amyloidosis Market (2018-2034) by Treatment Type
- 16.2.1 Market Overview
- 16.2.2 Chemotherapy
- 16.2.3 Targeted Therapy
- 16.2.4 Stem Cell Transplant
- 16.2.5 Medication
- 16.2.5.1 Transthyretin Transport Inhibitor
- 16.2.5.2 Immunomodulatory Drugs
- 16.2.5.3 Monoclonal Antibodies
- 16.2.5.4 Proteasome Inhibitors
- 16.2.5.5 Others
- 16.2.6 Others
- 16.3 France Amyloidosis Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Parenteral
- 16.4 France Amyloidosis Market (2018-2034) by Distribution Channel
- 16.4.1 Market Overview
- 16.4.2 Hospital Pharmacies
- 16.4.3 Retail Pharmacies
- 16.4.4 Others
- 16.5 France Amyloidosis Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Specialty Clinics
- 16.5.4 Academic and Research Institutes
- 16.5.5 Others
- 17 Italy Amyloidosis Market (218-2034)
- 17.1 Italy Amyloidosis Market (2018-2034) by Type
- 17.1.1 Market Overview
- 17.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 17.1.3 AA Amyloidosis
- 17.1.4 Others
- 17.2 Italy Amyloidosis Market (2018-2034) by Treatment Type
- 17.2.1 Market Overview
- 17.2.2 Chemotherapy
- 17.2.3 Targeted Therapy
- 17.2.4 Stem Cell Transplant
- 17.2.5 Medication
- 17.2.5.1 Transthyretin Transport Inhibitor
- 17.2.5.2 Immunomodulatory Drugs
- 17.2.5.3 Monoclonal Antibodies
- 17.2.5.4 Proteasome Inhibitors
- 17.2.5.5 Others
- 17.2.6 Others
- 17.3 Italy Amyloidosis Market (2018-2034) by Route of Administration
- 17.3.1 Market Overview
- 17.3.2 Oral
- 17.3.3 Parenteral
- 17.4 Italy Amyloidosis Market (2018-2034) by Distribution Channel
- 17.4.1 Market Overview
- 17.4.2 Hospital Pharmacies
- 17.4.3 Retail Pharmacies
- 17.4.4 Others
- 17.5 Italy Amyloidosis Market (2018-2034) by End User
- 17.5.1 Market Overview
- 17.5.2 Hospitals
- 17.5.3 Specialty Clinics
- 17.5.4 Academic and Research Institutes
- 17.5.5 Others
- 18 Spain Amyloidosis Market (218-2034)
- 18.1 Spain Amyloidosis Market (2018-2034) by Type
- 18.1.1 Market Overview
- 18.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 18.1.3 AA Amyloidosis
- 18.1.4 Others
- 18.2 Spain Amyloidosis Market (2018-2034) by Treatment Type
- 18.2.1 Market Overview
- 18.2.2 Chemotherapy
- 18.2.3 Targeted Therapy
- 18.2.4 Stem Cell Transplant
- 18.2.5 Medication
- 18.2.5.1 Transthyretin Transport Inhibitor
- 18.2.5.2 Immunomodulatory Drugs
- 18.2.5.3 Monoclonal Antibodies
- 18.2.5.4 Proteasome Inhibitors
- 18.2.5.5 Others
- 18.2.6 Others
- 18.3 Spain Amyloidosis Market (2018-2034) by Route of Administration
- 18.3.1 Market Overview
- 18.3.2 Oral
- 18.3.3 Parenteral
- 18.4 Spain Amyloidosis Market (2018-2034) by Distribution Channel
- 18.4.1 Market Overview
- 18.4.2 Hospital Pharmacies
- 18.4.3 Retail Pharmacies
- 18.4.4 Others
- 18.5 Spain Amyloidosis Market (2018-2034) by End User
- 18.5.1 Market Overview
- 18.5.2 Hospitals
- 18.5.3 Specialty Clinics
- 18.5.4 Academic and Research Institutes
- 18.5.5 Others
- 19 Japan Amyloidosis Market
- 19.1 Japan Amyloidosis Market (2018-2034) by Type
- 19.1.1 Market Overview
- 19.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 19.1.3 AA Amyloidosis
- 19.1.4 Others
- 19.2 Japan Amyloidosis Market (2018-2034) by Treatment Type
- 19.2.1 Market Overview
- 19.2.2 Chemotherapy
- 19.2.3 Targeted Therapy
- 19.2.4 Stem Cell Transplant
- 19.2.5 Medication
- 19.2.5.1 Transthyretin Transport Inhibitor
- 19.2.5.2 Immunomodulatory Drugs
- 19.2.5.3 Monoclonal Antibodies
- 19.2.5.4 Proteasome Inhibitors
- 19.2.5.5 Others
- 19.2.6 Others
- 19.3 Japan Amyloidosis Market (2018-2034) by Route of Administration
- 19.3.1 Market Overview
- 19.3.2 Oral
- 19.3.3 Parenteral
- 19.4 Japan Amyloidosis Market (2018-2034) by Distribution Channel
- 19.4.1 Market Overview
- 19.4.2 Hospital Pharmacies
- 19.4.3 Retail Pharmacies
- 19.4.4 Others
- 19.5 Japan Amyloidosis Market (2018-2034) by End User
- 19.5.1 Market Overview
- 19.5.2 Hospitals
- 19.5.3 Specialty Clinics
- 19.5.4 Academic and Research Institutes
- 19.5.5 Others
- 20 India Amyloidosis Market
- 20.1 India Amyloidosis Market (2018-2034) by Type
- 20.1.1 Market Overview
- 20.1.2 AL amyloidosis (Immunoglobulin Light Chain Amyloidosis)
- 20.1.3 AA Amyloidosis
- 20.1.4 Others
- 20.2 India Amyloidosis Market (2018-2034) by Treatment Type
- 20.2.1 Market Overview
- 20.2.2 Chemotherapy
- 20.2.3 Targeted Therapy
- 20.2.4 Stem Cell Transplant
- 20.2.5 Medication
- 20.2.5.1 Transthyretin Transport Inhibitor
- 20.2.5.2 Immunomodulatory Drugs
- 20.2.5.3 Monoclonal Antibodies
- 20.2.5.4 Proteasome Inhibitors
- 20.2.5.5 Others
- 20.2.6 Others
- 20.3 India Amyloidosis Market (2018-2034) by Route of Administration
- 20.3.1 Market Overview
- 20.3.2 Oral
- 20.3.3 Parenteral
- 20.4 India Amyloidosis Market (2018-2034) by Distribution Channel
- 20.4.1 Market Overview
- 20.4.2 Hospital Pharmacies
- 20.4.3 Retail Pharmacies
- 20.4.4 Others
- 20.5 India Amyloidosis Market (2018-2034) by End User
- 20.5.1 Market Overview
- 20.5.2 Hospitals
- 20.5.3 Specialty Clinics
- 20.5.4 Academic and Research Institutes
- 20.5.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share by Top 5 Companies
- 27.2 Ac Pfizer Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Development
- 27.2.5 Certifications
- 27.3 Johnson & Johnson Services, Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Development
- 27.3.5 Certifications
- 27.4 Takeda Pharmaceutical Company Limited
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Development
- 27.4.5 Certifications
- 27.5 Bristol-Myers Squibb Company
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Development
- 27.5.5 Certifications
- 27.6 Amgen Inc.
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Development
- 27.6.5 Certifications
- 27.7 Novartis AG
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Development
- 27.7.5 Certifications
- 27.8 F. Hoffmann-La Roche Ltd
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Development
- 27.8.5 Certifications
- 27.9 Sanofi
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Development
- 27.9.5 Certifications
- 27.10 Alnylam Pharmaceuticals, Inc.
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Development
- 27.10.5 Certifications
- 27.11 Prothena
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Development
- 27.11.5 Certifications
- 28 Amyloidosis Market – Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
